Key terms
About CKPT
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CKPT news
Mar 22
12:30pm ET
Analysts’ Top Healthcare Picks: Milestone Pharmaceuticals (MIST), Checkpoint Therapeutics (CKPT)
Mar 22
8:46am ET
Checkpoint Therapeutics reports FY23 EPS ($3.17), consensus ($2.66)
Mar 18
4:25pm ET
Checkpoint Therapeutics Enhances Board with New Independent Director
Mar 18
8:17am ET
Checkpoint Therapeutics appoints Sharma to board of directors
Jan 31
10:56am ET
Biotech Alert: Searches spiking for these stocks today
No recent news articles are available for CKPT
No recent press releases are available for CKPT
CKPT Financials
Key terms
Ad Feedback
CKPT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CKPT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range